Reliv International, Inc (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, announced the launch of the LunaRich® Super Pack, a product package designed to facilitate new customer purchases and new distributor sign-ups. The launch took place through an online event on Saturday, March 29. Reliv International, Inc (NASDAQ:RELV) shares after opening at $2.26 moved to $2.75 on last trade day and at the end of the day closed at $2.62. Company price to sales ratio in past twelve months was calculated as 0.49 and price to cash ratio as 4.95. Reliv International, Inc (NASDAQ:RELV) showed a positive weekly performance of 22.43%.
Ever since adjusting its fourth quarter 2013 and first quarter 2014 revenue outlook, Vimicro International Corporation (ADR) (NASDAQ:VIMC) has remained an attractive stock for investors. The stock has a positive gain pattern with significant amount of shares changing hands in the past sessions. The fabless chip company announced that its revenue expectation for the fourth quarter is in the range of $21 – $22 million, up from the previous range of $13.5 – $15.5 million. The first quarter is expected to come in with $15 – $17 million revenue, above $7.9 million noted in the first quarter of 2013. Vimicro International Corporation (ADR) (NASDAQ:VIMC) shares advanced 21.81% in last trading session and ended the day on $4.97. Vimicro International Corporation (ADR) (NASDAQ:VIMC) return on equity ratio is recorded as 3.10% and its return on assets is 1.60%. Vimicro International Corporation (ADR) (NASDAQ:VIMC) yearly performance is 203.05%.
MannKind Corporation(NASDAQ:MNKD)’s shares dropped 15.94% to $4.06. An initial review of MannKind Corp’s experimental inhaled insulin device, Afrezza, by U.S. Food and Drug Administration staff raised multiple questions about its safety and effectiveness in treating diabetes. The reviewers issued their report before a meeting on April 1 of outside advisers to the FDA who will discuss clinical trial data and advise on whether the product should be approved. Afrezza is a whistle-sized inhaler designed to deliver more effective, rapid-acting insulin than injectable products offered by Eli Lilly and Co. and Denmark’s Novo Nordisk. The FDA staff review raised questions about dosing, missing data, bronchospasms, and Afrezza’s affect on lung function. MannKind Corporation(NASDAQ:MNKD) shares moved down 16.77% in last trading session and was closed at $4.02, while trading in range of $ 3.80 – 4.60. MannKind Corporation(NASDAQ:MNKD) year to date (YTD) performance is -22.69%.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), in whose stock analysts at TheStreet remain bearish with a sell recommendation, could get away with an opportunity to develop a generic version of Copaxone if the U.S. top court doesn’t grant the wishes of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA). In July 2013, a court ruling favored the position of MNTA and other cheap generic drug manufacturers seeking to bring to the market a generic version of Copaxone. But TEVA is firmly against such moves as they will effectively erode its drug patent protection and expose it to intense market competition. A decision as to whether the top court will review the earlier ruling is expected earliest on March 31. Momenta Pharmaceuticals is still soaked in losses. The company reported loss of 59 cents against 45 cents loss which Wall Street expected in its most recent quarter. Momenta Pharmaceuticals, Inc.(NASDAQ:MNTA) weekly performance is -18.65%. On last trading day company shares ended up $11.65. Momenta Pharmaceuticals, Inc.(NASDAQ:MNTA) distance from 50-day simple moving average (SMA50) is -29.85%. Analysts mean target Price for the company is $19.75.